CDC advisers to weigh limits on Johnson & Johnson vaccine because of continued blood clot issues – The Washington Post

The panel is “certainly going to get some updates between the [April] pause and now — how many more cases are there [now] compared to before, and are there certain populations that may be at increased risk, based on age, gender and comorbidities,” said one clinician familiar with the agenda, who, like others, spoke on the condition of anonymity because they were not authorized to discuss it publicly.

Leave a comment

Your email address will not be published. Required fields are marked *